Abstract
Pediatrix Medical will report fourth-quarter results on February 19, 2026 Pre-Market; this preview synthesizes the latest quarterly actuals and current-quarter forecasts to outline revenue, margins, EPS, and operational themes likely to drive investor reaction.
Market Forecast
Based on the latest model outputs, the market expects Pediatrix Medical to deliver revenue of $486.23 million this quarter, adjusted EPS of $0.54, and EBIT of $62.89 million, implying year-over-year changes of 0.01%, 46.92%, and 32.85%, respectively. The company’s core revenue mix remains concentrated in patient services, and near-term execution focus centers on stabilizing volumes and maintaining pricing integrity while managing payor mix.
The most promising revenue contributor is patient services, which generated $422.18 million last quarter and remains the central driver of performance; segment-level year-over-year growth was not disclosed.
Last Quarter Review
Pediatrix Medical posted revenue of $492.88 million, a gross profit margin of 28.48%, GAAP net profit attributable to the parent company of $71.71 million, a net profit margin of 14.55%, and adjusted EPS of $0.67; revenue declined 3.58% year-over-year, while adjusted EPS increased 52.27% year-over-year. Net profit rose 82.65% quarter-on-quarter, underscoring improved cost discipline and earnings quality relative to the prior quarter.
Main business revenue contributions were: patient services at $422.18 million, hospital contract management fees at $67.73 million, and management services and other at $2.97 million; year-over-year changes by segment were not provided.
Current Quarter Outlook
Patient Services
Patient services remains the largest contributor to Pediatrix Medical’s top line at $422.18 million last quarter, and the principal lever for revenue, margin, and EPS trend this quarter. Key near-term performance drivers include volume stability across neonatology and maternal-fetal medicine, calendar-day mix within the reporting quarter, and local market variations in case acuity. The improved EPS trajectory in the previous quarter suggests that cost controls and physician staffing efficiency are feeding through to margins; sustaining these gains in the core patient services area will be essential to meet the forecasted 46.92% EPS year-over-year increase. Payor mix and the cadence of commercial contract renewals are also pivotal, as reimbursement rates and denial trends can materially affect realized revenue and service-level profitability.
Hospital Contract Management Fees
Hospital contract management fees contributed $67.73 million last quarter and serve as a stable offset to volume-sensitive patient services. This quarter’s EBIT forecast growth of 32.85% year-over-year points to incremental operating leverage if administrative overhead remains controlled and if contract terms are upheld without unanticipated concessions. The revenue profile in this line is typically less variable than patient-facing billing; however, timing of renewals, performance-based incentives, and any scope changes can affect contribution margins in the quarter. If management maintains process rigor around contract execution, the combined effect with patient services cost management can support the projected EPS expansion, even under flat revenue expectations.
Management Services and Other
Management services and other represented $2.97 million last quarter and, while small, can serve as a margin enhancer when bundled with broader services. In the current quarter, this area’s influence will be more qualitative than quantitative, supporting operational efficiency and system-level integration that underpin cost containment. Any incremental wins or expanded service arrangements could provide upside to EBIT if overhead allocations remain optimized. The emphasis should remain on administrative throughput, billing accuracy, and collections efficiency to protect cash conversion and reduce revenue leakage.
Factors Most Impacting the Stock Price This Quarter
Three variables are likely to frame investor reaction on the print: the relationship between EPS delivery and revenue stability, the durability of margin improvements, and any commentary on payor or collections dynamics. With revenue forecast at $486.23 million (up 0.01% year-over-year), the stock’s response will hinge on whether management can demonstrate that margin gains are sustainable and not solely driven by transient cost timing or one-offs; investors will scrutinize gross margin and operating expense trends relative to prior quarter trajectories. The 46.92% projected year-over-year increase in EPS sets a high bar; visibility on volume mix, staffing efficiency, and reimbursement robustness will be key to validating that step-up. Management commentary on denials, days sales outstanding, and contract renewals will also matter, as these determine near-term cash flow strength and the likelihood of achieving the 32.85% year-over-year EBIT growth embedded in expectations.
Analyst Opinions
Across the available coverage within the defined timeframe, the published institutional view is bullish. The consensus expectation reflected in current-quarter forecasts emphasizes a supportive setup for EPS and EBIT growth despite near-flat revenue projections, aligning with constructive sentiment on near-term operating leverage. In this context, analysts highlight that cost management, staffing efficiency, and incremental process improvements can reinforce margin gains, while the core patient services base provides a consistent revenue foundation; this perspective frames a majority bullish ratio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments